Emergent Revises Upward 2010 Financial Forecast
Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]
August 3, 2010
Tags: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, Strategic National Stockpile, United States., US government Posted in: Anthrax vaccines, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri 
No Comments
Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax
ROCKVILLE, Md., Jul 14, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale [...]
July 15, 2010
Tags: Anthrax vaccines, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease, US government Posted in: Anthrax vaccines, Biosolutions, Biothrax, Emergent BioSolutions, Health Care, fuad el-hibri No Comments
Emergent BioSolutions Hosts Biopreparedness Roundtable for NATO Parliamentarians
ROCKVILLE, Md., Jul 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. (NYSE:EBS) is hosting “Bioterrorism Prevention, Preparedness and Response,” a forum organized for members of the North Atlantic Treaty Organization (NATO) Parliamentary Assembly (PA) to raise global awareness of the importance of biopreparedness. The visiting delegation [...]
July 13, 2010
Tags: Anthrax vaccines, Emergent BioSolutions, Food and Drug Administration, NATO, United States Department of Health and Human Services, United States. Posted in: Emergent BioSolutions, NATO, North Atlantic Treaty Organization, United States Department of Health and Human Services, Vaccine No Comments
Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments
ROCKVILLE, MD, June 24, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) led by CEO Fuad El-Hibri,announced today that it has completed separate international sales and deliveries of BioThrax® (Anthrax Vaccine Adsorbed) to governments of several allied nations. The company’s international sales efforts have resulted in these sales [...]
July 7, 2010
Tags: Anthrax vaccines, BioSolutions Inc, Biothrax, Emergent BioSolutions, Food and Drug Administration, Infectious disease Posted in: Anthrax vaccines, Biothrax, El-Hibri, Emergent BioSolutions, Vaccine, fuad el-hibri No Comments
Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares
CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]
August 14, 2009
Tags: Anthrax, Anthrax vaccines, Emergent BioSolutions, Health, Infectious disease, Public health, U.S. Food and Drug Administration, Vaccine Posted in: Board of Directors, CEO, Emergent BioSolutions, Shareholders, fuad el-hibri No Comments
STATEMENT BY FUAD EL-HIBRI, EMERGENT BIOSOLUTIONS CHAIRMAN AND CHIEF EXECUTIVE OFFICER, ON THE PASSING OF ADMIRAL WILLIAM CROWE, JR., FORMER BOARD MEMBER.
ROCKVILLE, MD, October 19, 2007— Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions, issued the following statement on the passing of Admiral William Crowe, Jr., who served on the company’s Board of Directors from 1998-2005.
“I was deeply saddened to learn of the passing of my dear friend and former colleague, the honorable Admiral [...]
July 15, 2009
Tags: Anthrax vaccines, Board of Directors, Chief executive officer, Emergent BioSolutions, Health, Infectious disease, United States., US Food and Drug Administration. Posted in: Uncategorized No Comments
U.S. Government To Purchase Additional 14.5 Million Doses Of Biothrax® Under New Contract Valued At Up To $404 Million
New contract extends USG’s commitment to purchase BioThrax through 3Q 2011 and is a follow-on to the existing 2007, $448 million contract
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a new, multi-year, firm fixed price contract with the U.S. Department of Health and Human Services (HHS) to supply an additional 14.5 million [...]
July 13, 2009
Tags: Anthrax, Anthrax vaccines, Emergent BioSolutions, Private Securities Litigation Reform Act, Strategic National Stockpile, U.S. Food and Drug Administration, U.S. Government, United States Department of Health and Human Services, United States. Posted in: Uncategorized No Comments
Emergent Biosolutions Appoints Dr. W. James Jackson As Chief Scientific Officer
Emergent BioSolutions Inc. (NYSE: EBS) announced today that W. James Jackson, Ph.D., has been appointed chief scientific officer, effective immediately. Dr. Jackson will report directly to Fuad El-Hibri, chairman and chief executive officer.
As CSO, Dr. Jackson will lead the company’s scientific evaluation of new products and technology platforms and will be responsible for building and [...]
July 13, 2009
Tags: Anthrax vaccines, Biotechnology and Pharmaceuticals, Business, Chief executive officer, Infectious disease, Pharmaceutical, Research and development, U.S. Food and Drug Administration, University of Georgia. Posted in: Uncategorized No Comments